Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.
The Guardant360® assay is a breakthrough liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw in approximately seven days upon receipt in the US laboratory. Since its launch in 2014, the Guardant360® assay has been ordered by more than 7,000 oncologists over 150,000 times for patients with advanced cancer to help select treatment.
GuardantOMNI™, launched in 2017, is designed for biopharmaceutical customers to use as a comprehensive genomic profiling tool to help accelerate clinical development programs in immuno-oncology and targeted therapy.
Search Location
Loading...Address:
3 Fusionopolis Link, # 02-11,
Nexus @ One-North,
Singapore 138543.
Telephone:
+65 63056523 / +65 63056520
WhatsApp Hotline:
+65 8940 0360
Email:
Media inquiries:
Guardant Health Japan Corp.
Address:
27F Shiodome Sumitomo Bldg.,
1-9-2 Higashi-shimbashi, Minato-ku,
Tokyo, 105-0021, Japan.
Email:
© 2019 Guardant Health AMEA ALL RIGHTS RESERVED
